OK · State regulatory reference
Oklahoma.
Moderate
Oklahoma permits telemedicine to establish a physician-patient relationship and initiate treatment without a prior in-person exam, under Board of Medical Licensure rules OAC 435:10-7-12/13 and 59 O.S. § 478.1. Compounding under Board of Pharmacy Title 535 (OAC 535:15-10-53 non-sterile, 535:15-10-55 sterile) follows USP-consistent facility standards and generally prohibits compounding a commercially available drug product absent a documented patient-specific need. No documented Oklahoma board or Attorney General enforcement specific to peptides or GLP-1 compounding was found.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
Under OAC 435:10-7-12/13, an Oklahoma-licensed physician may establish the relationship and prescribe via real-time audio-video (audio-only and questionnaire-only encounters excluded); 59 O.S. § 478.1 bars using telemedicine to establish a relationship for prescribing opiates, benzodiazepines, or carisoprodol, with narrow MAT exceptions.
Compounding
Oklahoma has no GLP-1/semaglutide-specific rule; OAC 535:15-10-53's prohibition on compounding commercially available drug products (absent a documented patient-specific need) is the operative constraint on copying FDA-approved GLP-1s now that shortages have resolved.
Sources